Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658468 | 1.00 | KMT2A (0.56) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL12928621 | 1.00 | KMT2A (0.56) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL17826082 | 1.00 | KMT2A (0.56) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL4300738 | 0.93 | KMT2A (0.58) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL29650664 | 0.93 | KMT2A (0.58) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL20504185 | 0.93 | KMT2A (0.58) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL17446830 | 0.91 | PTPN1 (0.53) | KMT2ACASP3PTPN1TLR2 | |
| SCHEMBL30919288 | 0.91 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL17790570 | 0.91 | KMT2A (0.56) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL13492286 | 0.91 | TLR2 (0.49) | KMT2ACASP3MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711368-A1 | AZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2026-03-18 | — | — | EP | disclosed |
| CN-120053682-A | Multi-drug linked combination drug conjugate and application thereof | 上海睿智医药研究集团有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025043696-A1 | ANTIVIRAL POLYPEPTIDE ANALOGUE | 上海多米瑞生物技术有限公司 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024251275-A1 | AZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | 成都麻沸散医药科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-119101054-A | Azepine compound, and composition and application thereof | 成都麻沸散医药科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-2766364-B1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-118239872-A | Acrylamide modified cysteine and synthesis and application thereof | 南京农业大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-111836616-B | Injectable solution with pH 7 comprising at least one basal insulin with PI between 5.8 and 8.5 and a copolyamino acid with carboxylate charge and hydrophobic group | 阿道恰公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116333092-A | Teriparatide lipidated derivatives | 正大天晴药业集团股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| CN-115677827-A | Peptide compounds | 深圳市健元医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115531602-A | Amino acid hydrogel for promoting gastric ulcer healing and preparation method thereof | 福州大学 | 2022-12-30 | — | — | CN | disclosed |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2022-12-29 | — | — | US | disclosed |
| EP-4089103-A1 | CLPCP PROTEASE-BINDING CYCLIC HEPTAPEPTIDES | Universität Duisburg-Essen (DE) | 2022-11-16 | — | — | EP | disclosed |
| CN-113214168-B | Method for synthesizing cyclic dipeptide containing glutamic acid and aspartic acid by solid-liquid combination | 陕西慧康生物科技有限责任公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | KMT2A 3929/4885CASP3 1216/4885PTPN1 3645/4885 |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | KMT2A 4716/4885CASP3 3315/4885PTPN1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.